Neuroinflammation in fibromyalgia and CRPS is multifactorial
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In his Review article (Neurogenic neuro inflammation in fibromyalgia and com plex regional pain syndrome. Nat. Rev. Rheumatol. 11, 639-648; 2015) 1 , Geoffrey Littlejohn ascribes neuroinflammation to a "neurogenic" origin, presumably triggered by pain and stress. However, attribution of neuro inflammation and central sensitization to a primary neurogenic origin is premature without integrating the welldocumented coexistence of small intestine bacterial overgrowth (SIBO, one type of gastrointes tinal dysbiosis), vitamin D deficiency, and mitochondrial dysfunction. Littlejohn 1 notes that chronic pain has been associated with lipopolysaccharide (LPS)-stimulated proinflammatory cytokines (particularly IFNγ and TNF); however, he does not pursue this line of thought to con nect it to relevant literature showing clear evidence of gastrointestinal dysbiosis and increased intestinal permeability in patients with fibromyalgia and complex regional pain syndrome (CRPS). The gastrointestinal tract is the most abundant source of LPS, systemic absorption of which is increased by SIBO and increased intestinal permeabil ity. In 1999, Pimentel et al. 2 showed that oral administration of antibiotics led to alleviation of pain and other clinical measures of fibro myalgia. In 2004, Pimentel et al. 3 showed that among 42 fibromyalgia patients, all (100%) showed laboratory evidence of SIBO, sever ity of which correlated positively with severity of fibromalgia. In that same year, Wallace and Hallegua 4 showed that eradication of SIBO with antimicrobial therapy led to clini cal improvements in fibromyalgia patients in direct proportion to antimicrobial efficacy. In 2008, Goebel et al. 5 documented that patients with fibromyalgia and CRPS have intestinal hyperpermeability; mucosal "leakiness" was highest in patients with CRPS, indicating a strong gastrointestinal component to the illness. In 2013, Reichenberger et al. 6 showed that CRPS patients have a distinct alteration in their gastrointestinal microbiome char acterized by reduced diversity and signifi cantly increased levels of Proteobacteria. LPS from Gramnegative bacteria is pow erfully proinflammatory and is known to trigger microglial activation via Tolllike receptor 4; experimental studies have shown that LPS promotes muscle mitochondrial impairment, peripheral hyperalgesia, and central sensitization 7 . Vitamin D deficiency is prevalent in chronic pain and fibr+omyalgia patients and promotes pain sensitization, myalgia and bone pain (osteomalacia) 8 Mitochondrial dysfunction, noted in fibromyalgia 13 and CRPS 14 , may be trig gered by gastrointestinal dysbiosis via LPS, Dlactate, hydrogen sulfide, and inflamma tion; mitochondrial dysfunction exacerbates and perpetuates microglial activation and glutaminergic neurotransmission 15 , thereby promoting pain sensitization centrally while also contributing to muscle pain periph erally 7 . Treatment of mitochondrial dys function with ubiquinone alleviates many biochemical and clinical manifestations of fibromyalgia 13 . Thus, neuroinflammation in fibromyalgia and CRPS has biological contributions includ ing gastrointestinal dysbiosis, vitamin D defi ciency, and mitochondrial dysfunction. These independent contributions commonly co exist, and each of these is additive/synergistic with the others in the promotion of periph eral and central hyperalgesia. The consistent painalleviating benefits of treatments for intestinal dysbiosis (antibiotics), vitamin D deficiency (supplementation) and mitochon drial dysfunction (ubiquinone) establish that these painful conditions are multifactorial and maintained by ongoing physiologic insults, each of which is treatable. 
